GNFT - הכנסה תפעולית לפני ניכוי פחת GENFIT

The competent French management of Genfit S.A. (GNFT) effectively manages intellectual property and transparent partnership revenues. EBITDA confirms this potential, where the 0.00 level records fresh values. Risks are associated with the dependence on a narrow niche of rare liver pathology therapies and the maintenance of a scientific advantage during clinical trials.

This metric measures the actual cash flow from core operations before taxes and interest, excluding any accounting assumptions. The current value of 0.00 reflects the ability of Genfit S.A. (GNFT) to monetize the drug Iqirvo and license payments, which allows for an assessment of the biopharmaceutical business's resilience to market shocks and commercialization efficiency through the EBITDA_Co trend.